Has Corey Langer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,651,431 in general payments to Corey Langer, MD across 445 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Corey Langer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Corey Langer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Corey Langer, MD

Hematology & Oncology · Philadelphia, PANPI 1811918501

Payments from drug & device makers

$7,651,431in general payments, 2019–2025

Across 445 payments — averaging $17,194 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$3.4M
Amgen$2.6M
Incyte Corporation$904K
Takeda Pharmaceuticals U.S.A., Inc.$270K
AstraZeneca$103K
Clovis Oncology, Inc.$99K
plus $284K from 34 others

$12,291in research payments, 2019–2025

Across 2 payments — averaging $6145.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$9K
Bristol Myers Squibb$3K

What the payments were for

Consulting fees$306,15062%
Speaking & faculty fees$91,38819%
Travel & lodging$84,38917%
Food & beverage$9,3062%
Education$1,0240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	152	$3,350,703
Amgen	22	$2,640,861
Incyte Corporation	5	$903,500
Takeda Pharmaceuticals U.S.A., Inc.	48	$270,203
AstraZeneca	39	$103,462
Clovis Oncology, Inc.	3	$98,688
Novocure Inc.	19	$68,418
Bristol Myers Squibb	2	$24,549
Sanofi	7	$23,365
GSK	4	$19,750
Catalyst Pharmaceuticals, Inc.	6	$15,622
Jazz Pharmaceuticals Inc.	16	$11,703
Astrazeneca UK Limited	13	$10,854
Gilead	12	$10,358
Genentech USA, Inc.	21	$10,269
Lilly USA, LLC	4	$9,721
Boehringer Ingelheim	2	$8,140
Pfizer	2	$7,400
Novartis	6	$7,143
Daiichi Sankyo Inc.	7	$6,385
Regeneron Healthcare Solutions, Inc.	13	$6,341
Johnson & Johnson	10	$6,265
Dr.reddy's Laboratories,inc.	1	$5,000
Eli Lilly	2	$4,375
Janssen Scientific Affairs, LLC	3	$4,053
Janssen Research & Development, LLC	4	$3,900
G1 Therapeutics, Inc.	1	$3,480
Eisai Inc.	1	$3,420
Regeneron	5	$3,032
Blueprint Medicines Corporation	1	$2,156
Taiho Oncology, Inc.	2	$2,084
Genentech, Inc.	1	$1,980
Exelixis Inc.	3	$1,980
Varian Medical Systems, Inc.	1	$1,200
EMD Serono, Inc.	1	$500
Fosun Pharma USA Inc.	1	$181
Bayer	2	$173
Mirati Therapeutics, Inc.	1	$155
Foundation Medicine, Inc.	1	$49
Rigel Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TAGRISSO$35,710
KEYTRUDA$33,664
IMFINZI$24,203
ALUNBRIG$22,388
LIBTAYO$16,323
FIRDAPSE$15,500
ZEPZELCA$11,270
RYBREVANT$9,911
TECENTRIQ$9,310
Enhertu$8,335
Alecensa$7,179
MEKINIST$7,046
TAFINLAR$7,046
XALKORI$5,600
ALIMTA$5,250
LUMAKRAS$4,802
OPTUNE LUA (NOVOTTF-200T)$3,704
COSELA$3,480
LENVIMA$3,420
IMDELLTRA (AMG 757)$2,058

How this compares

$7,651,431 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$98,671

Medicare patients

252

Services billed

705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	27	$642
Prednisone	71	$559
Albuterol Sulfate HfaAlbuterol Sulfate	11	$224
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	17	$177
Azithromycin	25	$128
Methylprednisolone	21	$120
Alprazolam	11	$108
Ondansetron Hcl	19	$104
Gabapentin	16	$77

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Philadelphia

Stephen BagleyPhiladelphia$13.1M
Stephen SchusterPhiladelphia$9.5M
Pooja GhataliaPhiladelphia$8.3M
Alfred GarfallPhiladelphia$7.6M
Charu AggarwalPhiladelphia$7M
Marcela MausPhiladelphia$4.4M
Catherine LaiPhiladelphia$3.8M
James StevensonPhiladelphia$3.4M
Tara MitchellPhiladelphia$3.2M
Henry FungPhiladelphia$2.5M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →